WO1996041814A1 - Peptide, bronchodilatateur et agent facilitant l'ecoulement sanguin - Google Patents
Peptide, bronchodilatateur et agent facilitant l'ecoulement sanguin Download PDFInfo
- Publication number
- WO1996041814A1 WO1996041814A1 PCT/JP1996/001543 JP9601543W WO9641814A1 WO 1996041814 A1 WO1996041814 A1 WO 1996041814A1 JP 9601543 W JP9601543 W JP 9601543W WO 9641814 A1 WO9641814 A1 WO 9641814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- arg
- leu
- ser
- tyr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 143
- 230000017531 blood circulation Effects 0.000 title claims abstract description 28
- 229940124630 bronchodilator Drugs 0.000 title claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000007883 bronchodilation Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000126 substance Chemical group 0.000 claims description 4
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 14
- DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical compound NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 67
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 67
- 235000001014 amino acid Nutrition 0.000 description 67
- 229940024606 amino acid Drugs 0.000 description 67
- 150000001413 amino acids Chemical class 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 230000014759 maintenance of location Effects 0.000 description 30
- 239000011347 resin Substances 0.000 description 30
- 229920005989 resin Polymers 0.000 description 30
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 29
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 23
- -1 t-butoxycarbonyl group Chemical group 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 21
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 230000003287 optical effect Effects 0.000 description 18
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 17
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 17
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 14
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 13
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 13
- 239000012264 purified product Substances 0.000 description 13
- STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 210000002460 smooth muscle Anatomy 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 238000010532 solid phase synthesis reaction Methods 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 7
- RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 7
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 108010068380 arginylarginine Chemical group 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IYKVSFNGSWTTNZ-GUBZILKMSA-N Ala-Val-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IYKVSFNGSWTTNZ-GUBZILKMSA-N 0.000 description 6
- CGWVCWFQGXOUSJ-ULQDDVLXSA-N Arg-Tyr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O CGWVCWFQGXOUSJ-ULQDDVLXSA-N 0.000 description 6
- RYEWQKQXRJCHIO-SRVKXCTJSA-N Asp-Asn-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RYEWQKQXRJCHIO-SRVKXCTJSA-N 0.000 description 6
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 6
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 6
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 108010047857 aspartylglycine Proteins 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 108010000761 leucylarginine Proteins 0.000 description 6
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 5
- 101710176384 Peptide 1 Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000003779 hair growth Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 108010064775 protein C activator peptide Proteins 0.000 description 4
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 4
- ZAVSPTOJKOFMTA-SFHVURJKSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylmethoxyphenyl)propanoic acid Chemical compound C1=CC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CC=C1OCC1=CC=CC=C1 ZAVSPTOJKOFMTA-SFHVURJKSA-N 0.000 description 3
- DMBKPDOAQVGTST-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxypropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)COCC1=CC=CC=C1 DMBKPDOAQVGTST-LBPRGKRZSA-N 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 3
- 229960004484 carbachol Drugs 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- DXCXWVLIDGPHEA-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-[(4-ethylpiperazin-1-yl)methyl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCN(CC1)CC DXCXWVLIDGPHEA-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108010047562 NGR peptide Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- ZUSSTQCWRDLYJA-UHFFFAOYSA-N n-hydroxy-5-norbornene-2,3-dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(O)C1=O ZUSSTQCWRDLYJA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IEAOAWZLUGOPJX-INIZCTEOSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[1-(phenylmethoxymethyl)imidazol-4-yl]propanoic acid Chemical compound C1=NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CN1COCC1=CC=CC=C1 IEAOAWZLUGOPJX-INIZCTEOSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- VVNYDCGZZSTUBC-LURJTMIESA-N (2s)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(N)=O VVNYDCGZZSTUBC-LURJTMIESA-N 0.000 description 1
- CTXPLTPDOISPTE-YPMHNXCESA-N (2s,3r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)[C@@H](C)OCC1=CC=CC=C1 CTXPLTPDOISPTE-YPMHNXCESA-N 0.000 description 1
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- VPSXHKGJZJCWLV-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylpiperidin-4-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCN(CC1)CC VPSXHKGJZJCWLV-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical group CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- RXUBZLMIGSAPEJ-UHFFFAOYSA-N benzyl n-aminocarbamate Chemical compound NNC(=O)OCC1=CC=CC=C1 RXUBZLMIGSAPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 101150100654 pacC gene Proteins 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel peptide, a bronchodilator and a blood flow improving agent.
- VIP Vasoactive Intestinal Peptide
- cerebral intestinal peptide which has a blood flow promoting and blood pressure lowering action.
- VIP was extracted from pig intestine in 1970 and consists of 28 amino acid residues (S. I. Said, V. Mutt Science, 169, 1217 (1970)).
- PACAP Pulitary Adenylate Cyclase Activating Polypeptide
- VIP and PACAP are classified as peptides belonging to the glucagon family because their amino acid sequences are similar to the amino acid sequences of secretin and glucagon.
- VIP and PACAP have strong vasodilatory and blood flow-promoting effects, and are therefore expected to be effective in treating ulcers, morbidity, pressure ulcers, impotence, and the like, as well as in hair growth and hair growth.
- VIP and PACAP have a very strong effect of relaxing bronchial smooth muscle in the respiratory system, and have an effect of relieving smooth muscle contraction induced by stimulants such as acetylcholine, histamine, and mouth tonin. .
- the present invention is to provide a novel peptide having excellent bronchodilator activity and a superior blood flow increasing effect, and a bronchodilator and a blood flow improver containing the peptide as an active ingredient. With the goal.
- the present invention provides a compound represented by the general formula (1):
- N represents a -NH 2 or a Asn-NH 2 where at the same time, a is Ala, B is Val, C is Asn, D is not Thr, E is Leu, K is Asn, L is Ser, M is lie, and N is Asn-NH 2.
- the present invention provides a bronchodilator comprising the peptide or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a blood flow improving agent comprising the peptide or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the above peptide or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.
- the present invention provides a bronchodilator method comprising administering to a human an effective amount of the peptide or a pharmaceutically acceptable salt thereof.
- the present invention provides a method for improving blood flow, which comprises administering to a human an effective amount of the peptide or a pharmaceutically acceptable salt thereof.
- the present invention provides the use of the above peptide or a pharmaceutically acceptable salt thereof for bronchodilation.
- the present invention provides the use of the above peptide or a pharmaceutically acceptable salt thereof for improving blood flow.
- the peptide and the salt thereof of the present invention are excellent in sustaining bronchodilation by smooth muscle relaxing action. Therefore, the peptides of the present invention and salts thereof are useful as bronchodilators.
- the peptide of the present invention and a salt thereof have an excellent blood flow increasing effect, and are excellent in sustainability. Therefore, the peptide of the present invention and a salt thereof are also useful as a blood flow improving agent, and can exert a blood flow improving effect at a low dose.
- the peptide represented by the general formula (1) or (2) can be produced by a conventional method for synthesizing a known peptide.
- a conventional method for synthesizing a known peptide for example, “The Peptides j Vol. 1 (1966) [Schreder and Luhke, Academic Press, Ne York, USA], or“ Peptide synthesis ”[Izumiya et al., Maruzen Co., Ltd.
- the azide method, the acid chloride method, the acid anhydride method, the mixed acid anhydride method, the DCC method, the active ester method (P-nitrophenyl ester method, N-hydroxysuccinic acid method) can be synthesized by the imidoester method, cyanomethylester method, etc.), the method using Padward reagent K, the carboimidazole method, the redox method, the DCC-additive method (HONB, HOBt, HOSu), etc. .
- These methods can be applied to both the solid phase synthesis method and the liquid phase synthesis method.
- the so-called stepwise elongation method in which one amino acid is sequentially condensed to the C-terminal amino acid according to the amino acid sequence of the target peptide by the general method for synthesizing a polypeptide as described above, or It is also produced by the so-called fragment condensation method, in which each fragment is synthesized by dividing the peptide into several fragments and coupling them. Can be built.
- the method for merifi-norelet (erri fiel d, RB) ⁇ £ [Solid phase pepti de synthes is, J. Amer. Chem. Soc., 85, 2149-2159 (1963)].
- the amino acid sequence of the target peptide in the present invention, the amino acid sequence of the above general formula (1) or (2)
- an insoluble resin having a functional group capable of binding to a carboxyl group is added to an insoluble resin having a functional group capable of binding to a carboxyl group.
- the terminal amino acid is attached with its amino group protected.
- the free amino group obtained by deprotection of the amino group is successively peptide-bonded one by one to the amino group-protected amino acids having activated propyloxyl groups in accordance with the amino acid sequence. Repeat the deprotection to extend the amino acid residue to the 1st histidine residue. Subsequently, the peptide can be produced by desorbing the obtained peptide from the resin.
- the amino group involved in the peptide bond of the amino acid is protected (that is, the protecting group is bonded to the amino group) and deprotected (that is, the protecting group is removed), and the amino acid is involved in the peptide bond of the amino acid.
- Activation of the carboxyl group is required.
- a protecting group may be bonded to a functional group on the side chain of the amino acid, if necessary.
- protecting group used for protecting the amino group those usually used can be mentioned.
- alkyl esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and tert-butyl ester, benzyl ester, p-nitrobenzyl ester, methylbenzyl ester, P-chlorobenzyl ester, benzhydryl ester, benzyloxy Carbonyl hydrazide, tert-butyloxycarbonyl hydrazide, Trityl hydrazide And the like.
- the activation of the carboxyl group involved in the peptide bond can be performed by a conventionally known method as described above, and the reagent and the like used for the activation can be appropriately selected from known ones.
- the carboxyl group is reacted with various reagents, for example, by reacting the corresponding acid chloride, acid anhydride or mixed acid anhydride, azide, active ester ( For example, pentachlorophenol, P-nitrophenol, N-hydroxysuccinic acid imide, N-hydroxybenztriazole, N-hydroxyl-5-norbornene-2,3-dicarboximide, etc. Stell) may be formed.
- an amino acid having a functional group in a side chain it is preferable that the functional group is protected during the peptide bond formation reaction.
- the functional group of the side chain it is preferable to protect the functional group of the side chain.
- the protection of the functional group is performed by binding the protecting group by a commonly used method. After completion of the peptide synthesis, those protecting groups are removed.
- Examples of the protecting group for the imino group of His include benzyloxymethyl (Bom), tosyl (Tos), benzyl (Bzl), benzyloxycarbonyl (Z), and trityl.
- the Ser and Thr hydroxyl groups can be protected, for example, by esterification or etherification, but need not be.
- a protecting group introduced by the esterification for example, a lower alkanol group such as acetyl, an aroyl group such as benzoyl, a group derived from carbonic acid such as benzoyloxycarbonyl and ethyloxycarbonyl, and the like are preferable.
- the protective group introduced by etherification for example, groups such as benzyl (Bzl), tetrahydroviranyl, tert-butyl and the like are suitably used.
- protective groups for the hydroxyl of Tyr for example, base Njiru (Bz l), bromobenzyl O key aryloxycarbonyl (Br Z), dichloro base Njiru (Cl 2 - Bz l), benzyl O propoxycarbonyl two Le (Z), Asechiru And tosyl (Tos).
- protective groups for the Amino group of Lys for example, benzyl O alkoxycarbonyl (z), black hole base Nji Ruo alkoxycarbonyl (C Bok Z), dichloro base Njiru (C l 2 - Bz l) , t - And groups such as butoxycarbonyl (Boc) and tosyl (Tos).
- Examples of the protective group for the guanidino group of Arg include groups such as tosyl (Tos), nitro, benzyloxycarbonyl (Z), and triamyloxycarbonyl (Aoc).
- the protection of the carboxyl group of Asp is carried out, for example, by esterification with benzyl alcohol, methanol, ethanol, tert-butanol and the like.
- the reaction for forming a peptide bond is carried out by, for example, a carbodiimide reagent such as dicyclohexylcarpoimide (DCC) or carbopimidazole, tetraethyl pyrophosphate, benzotriazole-N-hydroquintrisdimethylaminophosphonide.
- a carbodiimide reagent such as dicyclohexylcarpoimide (DCC) or carbopimidazole, tetraethyl pyrophosphate, benzotriazole-N-hydroquintrisdimethylaminophosphonide.
- a condensing agent such as muhexafluorophosphoride salt (Bop reagent).
- any resin can be used as long as it has a functional group capable of binding to a carboxyl group.
- benzhydrylamine resin (BHA resin), chloromethyl resin, oxymethyl resin, aminomethyl resin, P-methylbenzhydrylamine resin (MBHA resin), 4-aminomethylphenoloxymethyl resin, 4-hydroxymethyl Phenoxymethyl resin, 41-year-old xymethylphenylacetamidomethyl resin (PAM resin) and the like.
- BHA resin benzhydrylamine resin
- MBHA resin P-methylbenzhydrylamine resin
- PAM resin 41-year-old xymethylphenylacetamidomethyl resin
- the binding of the amino acid to the resin and the elimination of the synthesized peptide from the resin can be carried out by a conventionally known method.
- Solvents used in the above solid phase synthesis include various solvents known to be usable for peptide bond formation, for example, anhydrous or hydrous dimethylformamide (DMF), dimethylsulfoxide (DMSO), pyridine
- DMF dimethylformamide
- DMSO dimethylsulfoxide
- pyridine pyridine
- chloroform, dioxane, dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate, N-methylpyrrolidone, hexamethylphosphate triamide (HMPA) and the like can be used.
- These solvents can be used alone or as a mixed solvent of two or more.
- the produced peptide can be desalted and purified according to a usual method.
- ion exchange chromatography on DEAE-cellulose, etc., partition chromatography on Sephadex LH-20, Sephadex G-25, silica gel Can be desalted and purified by reversed phase chromatography such as normal phase chromatography such as HPLC, ODS-silica gel, and high performance liquid chromatography.
- the pharmaceutically acceptable salt of the peptide represented by the above general formula (1) or (2) includes, for example, acetate, hydrochloride, phosphate and the like.
- a bronchodilator containing the peptide of the present invention or a salt thereof as an active ingredient is effective in suppressing and improving asthma and the like.
- the peptide of the present invention or a salt thereof When used as a bronchodilator, it can be administered as it is, but generally, it is mixed with various pharmaceutically acceptable carriers by a known method, and then is converted into a liquid, gel, It is administered after processing into a solid oral or parenteral formulation.
- the administration method include an inhalation method such as an inhalation aerosol, an injection administration method, and an application method.
- the dosage of the peptide or its salt when used as a bronchodilator is determined appropriately according to the purpose of use, the patient's symptoms, age, body weight, etc., and the administration method, but it is usually 1 ng to 1 mg per person per day. It is preferable to use in the range of about / Kg (body weight).
- the peptide of the present invention and its salt have an excellent blood flow increasing action, and the action is also excellent in persistence. Therefore, the blood flow improving agent containing the peptide of the present invention or a salt thereof as an active ingredient is effective for treatment of ulcer, morbidity, decubitus, impotence, hair growth, hair growth, and the like.
- the peptide of the present invention and its salt are used as a blood flow improving agent, it is mixed with a usual pharmaceutically acceptable carrier and processed into the form of a preparation. Is desirable.
- the resulting preparation is preferably sterile and isotonic with blood.
- a diluent commonly used in this field can be used.
- water, physiological saline and the like can be mentioned.
- a sufficient amount of food salt or glycerin for preparing an isotonic solution may be contained in the preparation in the form of an injection.
- the above preparations can contain ordinary buffers, soothing agents, preservatives, etc., and if necessary, coloring agents, preservatives, flavors, flavors, sweeteners, and other pharmaceuticals.
- the above active ingredient is dissolved in distilled water for injection at the time of use, and can be used as a solubilizer at the time of use.
- the preparation thus prepared can be administered by a method depending on the form. In the case of an injection, it is administered intravenously either alone or as a mixture with a normal replacement fluid such as amino acid.
- the dose of the peptide or its salt should be appropriately determined according to the purpose of use, symptoms, etc. ⁇ Normally, use in the range of 1 ng to 1 mgZkg (body weight) per person per day. It is preferable to administer the drug in 2 to 4 divided doses per day.
- FIG. 1 is a graph showing the change over time in the relaxation rate of bronchial smooth muscle when PAC AP is added.
- FIG. 2 is a graph showing a time-dependent change in the relaxation rate of bronchial smooth muscle when peptide 5 represented by SEQ ID NO: 5 was added.
- FIG. 3 is a graph showing the change over time in the relaxation rate of bronchial smooth muscle when VIP was added.
- FIG. 4 is a graph showing the time-dependent change in the relaxation rate of bronchial smooth muscle when peptide 11 represented by SEQ ID NO: 11 was added.
- LC-Module-l manufactured by Nippon Waters Limited
- DIC-370 manufactured by JASCO Corporation was used.
- Amino acid analysis was performed by hydrolyzing the peptide in 6N-HC1 (containing 0.1% phenol) at 110 ° C for 20 hours, and then using a Hitachi amino acid analyzer L-850 (manufactured by Hitachi, Ltd.). Was.
- a peptide synthesizer 9600 manufactured by Milligen Bioreserch was used as a solid phase synthesizer.
- Peptide 1 having an amino acid sequence represented by SEQ ID NO: 1 and having an amidated C-terminal carboxyl group was produced by solid phase synthesis and purification according to the following.
- Boc-Leu-OH 2imnol an amino protected amino acid corresponding to the amino acid residue at position 27 in the amino acid sequence, was dissolved in 4 ml of DCM. Transfer the solution to an amino acid activation vessel
- Boc-Leu-OH 2 mmol was dissolved in 4 ml of DCM, the solution was placed in an amino acid activation reaction vessel, and the same operation as above was repeated (so-called double force coupling method), followed by filtration. In this way, Boc-Leu-MB HA resin was obtained o
- Boc-Leu-MBHA resin was washed with 8 ml of DCM (4 times, 1 minute each) and filtered.
- This resin was stirred in a stream of argon gas under stirring in a 60% TFA-containing DCM solution 8 ml (20 minutes), DCM 1 ⁇ 21 (3 times, 15 seconds each), DI EA 1 ml DMF solution 3 ml (twice, Each 1 minute) and 8 ml of DMF (6 times, 40 seconds each) were processed in this order, and filtration was performed for each treatment.
- amino acids at the 25-position to the 1-position were sequentially coupled using the following amino-protected amino acids.
- the eluate corresponding to the peak of the target substance, peptide 1 was freeze-dried, and the high performance liquid chromatography yielded 63 mg of purified peptide with respect to 100 mg of the partially purified product of the above peptide.
- the purified peptide 1 was subjected to measurement of retention time in high performance liquid chromatography (HP LC), measurement of optical rotation, and amino acid analysis. The results are shown below.
- Example 2 a purified product of peptide 2 having the amino acid sequence represented by SEQ ID NO: 2 and having the c-terminal carboxyl group amidated was obtained.
- the retention time of high-performance liquid chromatography (HPLC) was measured, the optical rotation was measured, and amino acids were analyzed. The results are shown below.
- Example i a purified peptide 4 having an amino acid sequence represented by SEQ ID NO: 4 and having a carboxyl group at the C-terminal amide was obtained.
- the yield of this purified peptide is shown below.
- the retention time of high performance liquid chromatography (HPL C) was measured, the optical rotation was measured, and the amino acids were analyzed. The results are shown below. • Yield 84mg
- Example 7 As the resin, 704 m of Boc-Arg (Tos) -PAM resin (Amido group content: 0.68 nraiol / g, manufactured by Peptide Laboratories) to which an amino acid residue corresponding to the C-terminal amino acid residue was bound was used. Except for the above, a purified product of peptide 7 having the amino acid sequence represented by SEQ ID NO: 7 was obtained in the same manner as in Example 1. The yield of the purified peptide is shown below. In addition, we measured the retention time of high performance liquid chromatography (HPLC), measured the optical rotation, and performed amino acid analysis. The results are shown below.
- HPLC high performance liquid chromatography
- Example 2 In the same manner as in Example 1, a purified peptide 11 having the amino acid sequence represented by SEQ ID NO: 11 and having a carboxyl group at the C-terminal amide was obtained. The yield of this purified peptide is shown below. The retention time of high-performance liquid chromatography (HP LC) was measured, the optical rotation was measured, and amino acids were analyzed. The results are shown below. • Yield 87mg
- Example 2 In the same manner as in Example 1, a purified product of peptide 12 having an amino acid sequence represented by SEQ ID NO: 12 and having a carboxyl group at the C-terminal carboxylated was obtained. The yield of this purified peptide is shown below. The retention time of high-performance liquid chromatography (HPLC) was measured, the optical rotation was measured, and amino acids were analyzed. The results are shown below.
- HPLC high-performance liquid chromatography
- the resin is represented by SEQ ID NO: 13 in the same manner as in Example 1 except that 704 mg of Boc-Arg (Tos) -PAM resin to which an amino acid residue corresponding to the C-terminal amino acid residue is bonded is used.
- a purified product of peptide 13 having an amino acid sequence was obtained. The yield of this purified peptide is shown below.
- HPLC high-performance liquid chromatography
- Example 14 In the same manner as in Example 1, a purified product of peptide 14 having the amino acid sequence represented by SEQ ID NO: 14 and having the C-terminal carboxyl group amidated was obtained. The yield of the purified peptide is shown below. The retention time of high-performance liquid chromatography (HPLC) was measured, the optical rotation was measured, and amino acids were analyzed. The results are shown below. • Yield 64mg
- the jugular vein of a female guinea pig weighing 450 to 500 g was cut, the chest was opened, and the trachea was immediately removed.
- the trachea was immediately immersed in Krebs solution, cut into a ring shape, and the cartilage portions were connected to each other with a steel thread to form a chain. Then the smooth muscle part is connected
- the cartilage part opposite to the smooth muscle part was cut as described above. Approximate content of completed sample
- the relaxation effect was measured by sufficiently injecting oxygen and 6% carbon dioxide gas and dripping a 37 ° C crepe solution containing 0.1 imol / 1 carbachol from above at a flow rate of 0.33 ml / min. . Since a relaxation reaction occurs depending on the dose of the sample added to the drop solution, the relaxation effect on bronchial smooth muscle of VIP and PCAP and the peptide of the present invention was compared using this.
- Sample solutions of VIP, PCAP or the peptide of the present invention were each prepared at a concentration 100 times the final concentration in order to adjust the concentration in the organ bath.
- the sample solution 100 1 was dropped 30 minutes after the carbol-containing Kreps droplet.
- the degree of contraction of smooth muscle when carbachol was not added was 0, and the degree of contraction of smooth muscle when carbachol was added was 100, and the lowest degree of contraction (maximum relaxation value) A when the sample was added was determined.
- the maximum relaxation rate B was calculated from the following equation.
- half-hour T the time from the sample addition to the half of the maximum relaxation value
- FIG. 1 shows the results for PCAP
- FIG. 2 shows the results for peptide 5 obtained in Example 5
- FIG. 3 shows the results for VIP
- FIG. The maximum relaxation rate B of peptide 5 and peptide 11 at a dose of 3 M is 75% and 80%, respectively, and the half-life T is both 360 minutes or more. From these results, it was confirmed that the peptide of the present invention has a relaxing effect equivalent to that of VIP or PACAP, and has a longer action time than VIP or PACAP, that is, is superior in sustainability. .
- Table 1 shows the maximum relaxation rate B and half-life T at each dose of each peptide.
- Example 5 peptide 5 60 120 80> 360 75> 360
- Example 6 peptide 6 65 150 80> 360 75> 360
- Example 7 peptide 7 60 120 80 ⁇ 360 75> 360
- the purified peptides 1 to 15 obtained in Examples 1 to 15 were evaluated for the effect of increasing blood flow by the following method and compared with VIP and PACC.
- Blood pressure transducer DX-300, Nippon Koden
- SCK-512, Nippon Koden the dome kit
- heparinized saline 10U / ml
- blood pressure was measured with a strain blood pressure amplifier (AP-601G, Nihon Kohden).
- a blood flow measurement probe (FR-030T, Nihon Kohden) was attached to the right femoral artery, and connected to an electromagnetic blood flow meter (so-called-3200, Nihon Kohden) to measure blood flow.
- the administration of the drug into the artery was 100 pmol / kg.
- Table 2 shows the increased blood flow in rats receiving the peptide.
- Example 14 peptide 14 52.92 32.12 Peptide 15 of Example 15 52.63 ⁇ 31.05
- peptides 1 to 15 were each administered at 100 pmol / kg, almost no change in blood pressure was observed in each rat.
- Peptides 1 to 15 obtained in Examples 1 to 15 were dissolved in physiological saline, and intravenously administered to mice at a rate of 10 mg / kg. No deaths were observed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019970700797A KR100220404B1 (ko) | 1995-06-09 | 1996-06-06 | 펩티드, 기관지 확장제 및 혈류 개선제 |
US08/776,815 US5856303A (en) | 1995-06-09 | 1996-06-06 | Peptide, a bronchus-expanding agent, and a blood-flow-improving agent |
CA002196308A CA2196308C (en) | 1995-06-09 | 1996-06-06 | Peptide, bronchodilator and blood flow ameliorant |
AU59112/96A AU682638B2 (en) | 1995-06-09 | 1996-06-06 | Peptide, bronchodilator and blood flow ameliorant |
DE69630583T DE69630583T2 (de) | 1995-06-09 | 1996-06-06 | Peptide, bronchodilator und den blutstrom verbesserndes mittel |
AT96916331T ATE253590T1 (de) | 1995-06-09 | 1996-06-06 | Peptide, bronchodilator und den blutstrom verbesserndes mittel |
EP96916331A EP0796867B1 (en) | 1995-06-09 | 1996-06-06 | Peptide, bronchodilator and blood flow ameliorant |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7143581A JPH08333276A (ja) | 1995-06-09 | 1995-06-09 | ペプチド及び気管支拡張剤 |
JP7/143581 | 1995-06-09 | ||
JP7255370A JPH09100237A (ja) | 1995-10-02 | 1995-10-02 | 血流改善剤 |
JP7/255370 | 1995-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996041814A1 true WO1996041814A1 (fr) | 1996-12-27 |
Family
ID=26475273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/001543 WO1996041814A1 (fr) | 1995-06-09 | 1996-06-06 | Peptide, bronchodilatateur et agent facilitant l'ecoulement sanguin |
Country Status (8)
Country | Link |
---|---|
US (1) | US5856303A (ja) |
EP (1) | EP0796867B1 (ja) |
CN (1) | CN1124283C (ja) |
AT (1) | ATE253590T1 (ja) |
AU (1) | AU682638B2 (ja) |
CA (1) | CA2196308C (ja) |
DE (1) | DE69630583T2 (ja) |
WO (1) | WO1996041814A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002521390A (ja) * | 1998-07-20 | 2002-07-16 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Pacapのペプチド類似体 |
US6972319B1 (en) | 1999-09-28 | 2005-12-06 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use |
HUP0202175A3 (en) * | 1999-09-28 | 2005-01-28 | Bayer Corp Berkeley | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
WO2001060862A1 (en) * | 2000-02-18 | 2001-08-23 | Dabur Research Foundation | Vasoactive intestinal peptide analogs |
AU2000263935A1 (en) * | 2000-02-18 | 2001-08-27 | Dabur Research Foundation | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
US7507714B2 (en) | 2000-09-27 | 2009-03-24 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
ATE425762T1 (de) | 2001-11-06 | 2009-04-15 | Senju Pharma Co | Mittel zur behandlung von augentrockenheit und damit zusammenhangenden erkrankungen |
EP1571155B1 (en) * | 2002-11-27 | 2011-08-24 | Ils Inc. | Peptides and medicinal compositions containing the same |
JP5088471B2 (ja) * | 2007-07-25 | 2012-12-05 | Jsr株式会社 | 標的物質の検出方法およびラテックス凝集反応用試薬 |
KR102635553B1 (ko) * | 2018-12-28 | 2024-02-13 | 주식회사 리비옴 | 외래 단백질을 발현하는 미생물, 및 그의 용도 |
KR102527954B1 (ko) * | 2021-03-29 | 2023-05-03 | 주식회사 리비옴 | 외래 단백질을 발현하는 미생물, 및 그의 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62246595A (ja) * | 1986-04-17 | 1987-10-27 | Eisai Co Ltd | 気菅支拡張作用・降圧作用ペプタイド |
WO1988006598A1 (en) * | 1987-02-26 | 1988-09-07 | The Salk Institute Biotechnology/Industrial Associ | Vasoactive intestinal peptide analogs |
JPH04297498A (ja) * | 1991-03-27 | 1992-10-21 | Seikagaku Kogyo Co Ltd | ペプチド誘導体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4605641A (en) * | 1984-10-09 | 1986-08-12 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
US4734400A (en) * | 1984-10-09 | 1988-03-29 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
SE8705139D0 (sv) * | 1987-12-23 | 1987-12-23 | Trion Forskning & Utveckling | Forfarande for framstellning av ett stort antal peptidanaloger och nya peptidanaloger |
DK0463450T3 (da) * | 1990-06-26 | 1994-06-27 | Sanwa Kagaku Kenkyusho Co | Vasoaktive intestinale polypeptid-analoger og udnyttelsen heraf |
JPH0692991A (ja) * | 1991-02-28 | 1994-04-05 | Daicel Chem Ind Ltd | 新規活性ペプチド |
JPH06220090A (ja) * | 1993-01-22 | 1994-08-09 | Sanwa Kagaku Kenkyusho Co Ltd | ポリペプチド |
-
1996
- 1996-06-06 CN CN96190882A patent/CN1124283C/zh not_active Expired - Fee Related
- 1996-06-06 AU AU59112/96A patent/AU682638B2/en not_active Ceased
- 1996-06-06 EP EP96916331A patent/EP0796867B1/en not_active Expired - Lifetime
- 1996-06-06 CA CA002196308A patent/CA2196308C/en not_active Expired - Fee Related
- 1996-06-06 US US08/776,815 patent/US5856303A/en not_active Expired - Fee Related
- 1996-06-06 WO PCT/JP1996/001543 patent/WO1996041814A1/ja active IP Right Grant
- 1996-06-06 DE DE69630583T patent/DE69630583T2/de not_active Expired - Fee Related
- 1996-06-06 AT AT96916331T patent/ATE253590T1/de not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62246595A (ja) * | 1986-04-17 | 1987-10-27 | Eisai Co Ltd | 気菅支拡張作用・降圧作用ペプタイド |
WO1988006598A1 (en) * | 1987-02-26 | 1988-09-07 | The Salk Institute Biotechnology/Industrial Associ | Vasoactive intestinal peptide analogs |
JPH04297498A (ja) * | 1991-03-27 | 1992-10-21 | Seikagaku Kogyo Co Ltd | ペプチド誘導体 |
Also Published As
Publication number | Publication date |
---|---|
CN1124283C (zh) | 2003-10-15 |
AU5911296A (en) | 1997-01-09 |
DE69630583D1 (de) | 2003-12-11 |
AU682638B2 (en) | 1997-10-09 |
DE69630583T2 (de) | 2004-09-30 |
US5856303A (en) | 1999-01-05 |
EP0796867A1 (en) | 1997-09-24 |
CA2196308C (en) | 2000-10-17 |
EP0796867A4 (en) | 1999-10-20 |
ATE253590T1 (de) | 2003-11-15 |
CA2196308A1 (en) | 1996-12-27 |
CN1161043A (zh) | 1997-10-01 |
EP0796867B1 (en) | 2003-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5580953A (en) | Amylin antagonist peptides and uses therefor | |
KR100354897B1 (ko) | 성장호르몬방출성을갖는화합물 | |
US4835252A (en) | Vasoactive intestinal peptide analogs | |
RU2095368C1 (ru) | Циклические пептиды или их фармацевтически приемлемые соли, способ их получения | |
US4939224A (en) | Vasoactive intestinal peptide analogs | |
US4822774A (en) | Physiologically active peptide | |
EP0270376B1 (en) | Calcitonin gene-related peptide derivatives | |
WO1996041814A1 (fr) | Peptide, bronchodilatateur et agent facilitant l'ecoulement sanguin | |
AU2003284428B2 (en) | Peptides and medicinal compositions containing the same | |
HUT55803A (en) | Process for producing vip-analogues ii | |
US5149779A (en) | Humoral hypercalcemic factor antagonists | |
EP0246795A2 (en) | Synthetic natriuretic peptides | |
EP0307860B1 (en) | Cyclic GRF-analogs | |
IE53488B1 (en) | Crf and analogues | |
JP3137349B2 (ja) | ペプチド誘導体 | |
JPS61118399A (ja) | ペプチドホルモンの製造法 | |
JPH08333276A (ja) | ペプチド及び気管支拡張剤 | |
KR100220404B1 (ko) | 펩티드, 기관지 확장제 및 혈류 개선제 | |
JPH09100237A (ja) | 血流改善剤 | |
JP2001151799A (ja) | 新規ペプチド及びそれを含有する消化管運動抑制剤 | |
JP2002293799A (ja) | 新規ペプチド及びそれを含有する消化管運動抑制剤 | |
JPH03178993A (ja) | ポリペプチド誘導体及びカルシウム代謝改善剤 | |
JP2002003397A (ja) | 出血傾向治療剤 | |
JPH04352798A (ja) | ポリペプチド | |
JP2001278807A (ja) | 消化管運動抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96190882.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2196308 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970700797 Country of ref document: KR Ref document number: 1996916331 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08776815 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1019970700797 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1996916331 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970700797 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996916331 Country of ref document: EP |